For many patients with terminal/advanced cardiac failure, heart transplantation is the most
effective, durable treatment option, and offers the best prospects for a high quality of life. The …

Importance Although durable left ventricular assist device (LVAD) therapy has emerged as
an important treatment option for patients with advanced heart failure refractory to …

Despite advances in medical therapy for patients with stage C heart failure (HF), survival for
patients with advanced HF is< 20% at 5 years. Durable left ventricular assist device (dLVAD) …

Background Clinical trials inform on average efficacy, but individualized risk assessments for
outcome prediction are important in guiding treatment implementation. Objectives The …

Cardiogenic shock is an extreme manifestation of acute decompensated heart failure.
Cardiogenic shock is often caused by—and has traditionally been studied in the setting of …

Background US regulatory framework for advanced heart failure therapies (AHFT),
ventricular assist devices, and heart transplants, delegate eligibility decisions to …

Right heart failure is a major cause of morbidity and mortality following left ventricular assist
device implantation. Over the past few decades, the definition proposed by the Interagency …

Advanced heart failure (AHF) therapy allocation is vulnerable to bias related to subjective
assessments and poor group dynamics. Our objective was to determine whether an …

The medical management of patients supported with durable continuous flow left ventricular
assist device (LVAD) support encompasses pharmacological therapies administered in the …

Background Hemocompatibility-related adverse events affect patients after left ventricular
assist device (LVAD) implantation but are hard to predict. Objectives Dynamic risk modeling …